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ABSTRACT
We sought to investigate anticancer efficacy of a vascular disrupting agent (VDA) 
combretastatin A-4 phosphate (CA4P) in relation to tumor size among hepatocellular 
carcinomas (HCCs) in rats using magnetic resonance imaging (MRI) and postmortem 
techniques. Nineteen rats with 43 chemically-induced HCCs of 2.8–20.9 mm in size 
on liver cirrhosis received CA4P intravenously at 10 mg/kg. Tumor-diameter was 
measured by T2-weighted imaging (T2WI) to define microcancers (< 5 mm) versus 
larger HCCs. Vascular responses and tissue necrosis were detected by diffusion-
weighted imaging (DWI), contrast-enhanced T1-weighted imaging (CE-T1WI) and 
dynamic contrast enhanced (DCE-) MRI, which were validated by microangiography 
and histopathology. MRI revealed nearly complete necrosis in 5 out of 7 micro-
HCCs, but diverse therapeutic necrosis in larger HCCs with a positive correlation 
with tumor size. Necrosis in micro-HCCs was 36.9% more than that in larger HCCs. 
While increased diffusion coefficient (ADCdiff) suggested tumor necrosis, perfusion 
coefficient (ADCperf) indicated sharply decreased blood perfusion in cirrhotic liver 
together with a reduction in micro-HCCs. DCE revealed lowered tumor blood flow 
from intravascular into extravascular extracellular space (EES). Microangiography 
and histopathology revealed hypo- and hypervascularity in 4 and 3 micro-HCCs, 
massive, partial and minor degrees of tumoral necrosis in 5, 1 and 1 micro-HCCs 
respectively, and patchy necrotic foci in cirrhotic liver. CD34-PAS staining implicated 
that poorly vascularized micro-HCCs growing on liver cirrhosis tended to respond 
better to CA4P treatment. In this study, more complete CA4P-response occurred 
unexpectedly in micro-HCCs in rats, along with CA4P-induced necrotic foci in cirrhotic 
liver. These may help to plan clinical applications of VDAs in patients with HCCs and 
liver cirrhosis.
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INTRODUCTION
Combretastatin A4 phosphate (CA4P), as a 
Combretastatin family member initially derived from 
the South African willow tree Combretum caffrum [1], 
has become a leading vascular disrupting agent (VDA) 
for cancer therapy over the past decades [2]. CA4P takes 
effect as a potent and reversible tubulin depolymerizing 
agent to damage the existing tumor blood vessels 
[2, 3]. In a variety of implanted tumor models conducted 
in preclinical studies, CA4P induces rapid tumor 
vascular disruption as early as less than 1 hour resulting 
in extensive intratumoral necrosis within 12 hours 
[4, 5]. Nevertheless, VDA therapy features a viable rim 
consisting of layers of residual cancer cells at tumor 
periphery [5], subsequently leading to tumor relapse 
over several days [6]. This accentuates the necessity to 
combine CA4P treatment with other therapeutics such as 
chemotherapy [7], conventional radiotherapy [8], internal 
targeted radiotherapy [6] and antiangiogenic therapy [9, 
10]. To date, the safety and efficacy of CA4P plus chemo 
in patients with advanced non-small cell lung cancer 
[11–13], anaplastic thyroid cancer [14]  and platinum-
resistant ovarian cancer [13] have been under evaluations 
in phase II/III clinical trials. However, neither animal 
models of implanted tumors nor advanced clinical 
investigations on human cancers could forecast how CA4P 
functions in the early stage of primary HCCs. 
A positive correlation between increasing tumor 
volume and better therapeutic effect following VDA 
treatment has been noticed, since the antitumor efficacy 
of VDAs seemed to increase as tumors grew larger 
[15]. Such a correlation has been observed in multiple 
murine allograft and xenograft models in preclinical 
studies [16–18]. For instance, in the rat allograft model 
of subcutaneous rhabdomyosarcomas, CA4P efficacy in 
large tumors (≥ 14 cm3) was 16.6-fold stronger than that 
in small tumors (< 1 cm3) [17]. Similarly, intraperitoneal 
injection of ZD6126 led to nearly 90% necrosis in 
tumors larger than 1 g compared with only ~ 25% in 
the smaller ones of less than 0.3 g  in several mouse 
xenograft models including rodent sarcoma, squamous 
cell carcinoma and fibrosarcoma, as well as human renal 
cell carcinoma, Kaposi’s sarcoma and breast carcinoma 
[18]. Furthermore, this trend has also been implied in the 
clinical studies of advanced anaplastic thyroid carcinoma 
[19]. Despite these strong evidences, the underlying 
mechanisms remain to be unraveled. The inferior effects 
of VDAs in smaller tumors are likely due to their main 
portions of blood supply largely rooting from the vessels 
of the surrounding normal tissues [17, 18]. Indeed, tumors 
smaller than 5 mm in diameter often lack their own 
vasculature and are nourished by the nutrients diffused 
from their host organs [20]. 
As CA4P causes acute tumoral necrosis within 
hours, the conventional imaging criteria, Response 
Evaluation Criteria In Solid Tumors (RECIST) routinely 
adopted as the end points of VDA trials, cannot fully meet 
the growing needs of detecting early and transient tumor 
vascular reaction occurring prior to the change of tumor 
size [10]. Magnetic resonance imaging (MRI) is known to 
be of high sensitivity and excellent soft tissue contrast to 
identify rat liver tumors as small as 2 mm in size [21]. To 
date, multiparametric methods including dynamic contrast 
enhanced (DCE)-MRI and diffusion-weighted imaging 
(DWI) have been increasingly applied in both preclinical 
and clinical studies for acquiring functional information 
such as blood perfusion, fluid diffusion, blood volume, 
vascular permeability and extravascular extracellular 
space, and for noninvasively monitoring the real-time 
vascular responses to therapies [10, 22, 23].  
In the present study (Figure 1), we employed a 
chemically induced primary liver cancer model in rats, and 
evaluated the therapeutic efficacy of CA4P against HCCs 
in differential sizes, especially in the hepatic microcancer 
lesions in diameter ranging from 2 to 5 mm. Translationally, 
a 3.0T clinical MRI with a human wrist coil was utilized to 
characterize the in vivo early vascular responses to CA4P 
within 12 hours, and the imaging findings were further 
verified by ex vivo microangiography and histopathology. 
RESULTS
General conditions
In total, 43 primary HCC lesions, superimposed 
on varying degrees of liver cirrhosis, were successfully 
generated in the 19 rats. Among them, 7 rats were 
identified with micro-HCCs together with other 
17 larger HCCs (Table 1). All rats survived the 
experimental procedures including DENA gavage for 
hepatocarcinogenesis, gas anesthesia, MRI scanning with 
contrast administration, and intravenous CA4P treatment. 
All rats were sacrificed 12 h after CA4P treatment as the 
endpoint of in vivo study. 
Therapeutic efficacy enhanced with increasing 
tumor volume in larger HCCs
We first compared CA4P-induced tumoral necrosis 
among 43 HCCs in various tumor diameters to investigate 
the relationship between antitumor efficacy of CA4P and 
tumor size of primary HCCs (Figure 2). In line with the 
previous studies that CA4P showed increased activity 
in larger tumors [17, 18], CA4P efficacy in this study 
appeared positively correlated with the larger HCCs 
with diameters ranging from 5.7 mm to 20.9 mm, though 
showing great disparities in proportion of therapeutic 
necrosis (Figure 2A). 
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Paradoxical effects of CA4P in hepatic 
microcancers 
Surprisingly, extensive therapeutic tumoral necrosis 
frequently occurred in a subgroup of smaller HCCs, 
namely hepatic microcancers or micro-HCCs, which were 
smaller than 5 mm in diameter (Figure 2A). Tumoral 
necrosis ranging from 80% to nearly 100% was found in 
5 out of 7 microcancer lesions. Quantitatively, the rate of 
tumoral necrosis in the hepatic microcancers was 36.9% 
higher than that in the larger HCCs after CA4P treatment 
(Figure 2B). Intraindividual comparison of tumoral 
necrosis between these micro-HCCs and their larger-sized 
counterparts further verified this tendency (Table 1).
The early dramatic reactions in hepatic microcancers 
could be detected by real-time multiparametric MRI, as 
demonstrated by a representative hepatic microcancer 
Tumor 1 (Figure 3A). At baseline, the microcancer 
appeared slightly hyperintense on T2WI (Figure 3Aa1), 
nearly isointensity on T1WI (Figure 3Aa4) (Figure 3Aa2), 
moderately hyperintense on ADC map (Figure 3Aa3) and 
nearly unenhanced on CE-T1WI, suggestive of intrinsic 
hypovascularity. Twelve hours after CA4P treatment, 
massive tumoral necrosis was induced, revealed by the strong 
hyperintensity within entire tumor on T2WI (Figure 3Ab1), 
increased tumor ADC (Figure 3Ab3), and delayed contrast 
enhancement on CE-T1WI (Figure 3Ab4) compared with 
the precontrast T1WI (Figure 3Ab2). These imaging findings 
were validated by post-mortem microangiographic and 
histopathologic assessments (Figure 3B). Microangiography 
depicted the reduced tumor vessel density (Figure 3Ba). 
Gross specimen of tumor-bearing liver tissue (Figure 3Bb) 
and corresponding H&E stained photomicrograph confirmed 
the nearly complete tumoral necrosis superimposing on the 
cirrhotic liver (Figure 3Bc1, 3Bc2). 
Blood perfusion drop in cirrhotic liver 
attributable to massive necrosis in microcancer?
Given the general consensus that small tumors 
tend to poorly respond to VDA treatment due to the 
lack of their own established vasculature [18], we next 
examined our hypothesis that the blood supply in the 
surrounding cirrhotic liver had been lowered by CA4P 
as well and, therefore, it caused secondary necrosis in 
microcancers that are more vulnerable than cirrhotic liver 
to ischemia. Vascular behaviors both in the tumor and 
the surrounding cirrhotic liver were assessed by ADC 
calculations. Quantitative ADCperf indicated that, first at 
baseline, cirrhotic liver appears significantly hyperperfused 
relative to micro-HCCs (p < 0.05); secondly, CA4P 
sharply decreased blood perfusion in the surrounding liver 
(p < 0.05) with consequent drop of tumor perfusion 
(Figure 3Ca). This finding suggests that vasculature 
of cirrhotic liver was also severely targeted by CA4P, 
resulting in continuous liver ischemia for at least 12 h and 
a secondary damage to hepatic microcancers that totally 
Figure 1: Flow chart of experimental design. DENA: diethylnitrosamine; HCC: hepatocellular carcinoma; T2WI: T2-weighted 
imaging; CE: contrast-enhanced; T1WI: T1-weighted imaging; DWI: diffusion-weighted imaging; DCE: dynamic contrast enhanced; 
CA4P: combretastatin A4 phosphate; n: number of animals; t: number of tumors; Ø: diameter; h: hour(s); iv: intravenous(ly).
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rely on the supply from the surrounding liver. Meanwhile, 
tumor ADCdiff slightly rose, but was nearly unchanged 
in the surrounding liver, suggestive of tumoral necrosis 
formation (Figure 3Cb). Furthermore, necrosis-related drop 
of tumor blood flow from intravascular into extravascular 
extracellular space (EES) was also demonstrated by 
multiple DCE parameters, including significantly lowered 
Ktrans and AUC30, descending trend of ISpeak, and upward 
trend of TTP at 12 h (Figure 3D). 
Massive necrosis in hepatic microcancer along 
with scattered necrosis in cirrhosis liver
By histopathologic and microangiographic 
analyses, the tumor reactions to CA4P therapy were 
further compared in all those 7 microcancers Table 1. 
Consequently, nearly complete necrosis (82.8–96.5%) 
was induced in Tumor 1–5 of largely hypovascular 
and better differentiated (Grade I–III) micro-HCCs. 
(Figure 3B; Figure 4Aa1–a4, 4Ab1–b4, 4Ac1–c4, 
4Ad1–d4); while partial tumoral necrosis (23.2%) was 
seen in the hypervascular Grade III poorly differentiated 
Tumor 6 (Figure 4Ae1–e4) and minimal necrosis in 
Grade IV undifferentiated Tumor 7 that was composed 
largely with vascular lakes (Figure 4Af1–f4). To 
compare tumoral vascularity in microcancers with 
different therapeutic responses, CD34-PAS dual staining 
were used. In nearly completely necrotic micro-HCCs, 
rare CD34-positive channels were shown in the acute 
central necrosis, indicative of intrinsic hypovascularity 
(Figure 4a5–d5). However, in largely survived 
Tumor  6, CD34-positive capillaries were frequently 
observed, indicative of partial hypervascularity 
(Figure 4e5); while in Tumor 7, CD34 were diffusely 
expressed in the tumor cells that lined up the vascular 
lakes, indicative of vascular lakes and rich tumoral 
blood supply (Figure 4f5). On top of that, necrotic foci 
scattered in the cirrhotic liver as seen by microscopy 
Table 1: Intra-individual comparison of CA4P-induced tumor necrosis (%) among rats with both 
micro-HCCs and larger HCCs
Micro-HCCs Larger HCCs
Tumor 
code
CA4P-induced 
necrosis (%)
Tumor 
diameter (mm)
*Tumor 
vascularity
**Tumor 
differentiation
Tumor 
code
CA4P-induced 
necrosis (%)
Tumor  
diameter (mm)
*Tumor 
vascularity
**Tumor  
differentiation
Rat 1 Tumor 1 93.7 2.8 + I
#107 56.2 6.9 + II
#105 4.5 6.3 +++ III
Rat 2 Tumor 2 94.2 4.0 + I 
#012 57.4 9.0 ++ III
#007 47.5 5.9 + II
Rat 3 Tumor 3 90.5 4.3 + II
#166 69.4 7.6 ++ III
#164 46.2 6.9 ++ III
#165 21.8 9.7 ++ III
#168 16.4 6.5 ++ III 
#160 13.1 10.2 +++ III
#171 0.0 10.9 ++ III
#163 0.0 5.8 + II
Rat 4 Tumor 4 96. 5 4.9 + II #080 18.8 10.3 ++ III
Rat 5 Tumor 5 82.8 3.8 +++ III
#056 82.0 11.7 ++ III
#054 40.1 7.4 ++++ IV
Rat 6 Tumor 6 23.2 4.1 ++ III
#049 14.1 8.9 ++ II
#044 0.0 8.0 ++++ IV
Rat 7 Tumor 7 1.6 4.7 ++++ IV #133 79.1 9.4 + III
Mean ± SD 68.9 ± 39.4 4.1 ± 0.7 / / 33.3 ± 28.3 8.4 ± 1.8 / /
Note: 
*Tumor vascularity was semi-quantificationally scored: (+) similar vascular density to the liver parenchyma; (++) dense vasculature without vascular lakes; (+++) denser vasculature 
with variously sized vascular lakes; (++++) full of enlarged vascular lakes. **Tumor differentiation was graded by a modified 4-scale Edmondson and Steiner system [29]: (I) highly 
differentiated, consisting of tumor cells of moderate size arranged in thin trabeculae; (II) larger cells with active nuclear mitosis and possible pseudoglandular structures often with 
steatosis; (III) larger nuclei and more hyperchromatic or increased mitotic figures, granular and acidophilic cytoplasm, often with giant tumor cells; (IV) undifferentiated tumor 
cells with hyperchromatic nuclei and loss of trabecular pattern often with hypervascularity and angioinvasion.
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Figure 2: Comparison of CA4P therapeutic efficacy between micro-HCCs and larger HCCs. (A) Scatter plots of percentage 
of CA4P-induced tumoral necrosis in micro-HCCs ≤ 5 mm and in HCCs > 5 mm. Significant negative linear correlation was identified 
between CA4P-induced tumoral necrosis and tumors with diameter > 5 mm (*P < 0.05), while tumoral necrosis was not linearly correlated 
with tumors with diameters of ≤ 5 mm. (B) Bar chart comparing the mean percentage of CA4P-induced tumoral necrosis between micro-
HCCs of ≤ 5 mm and larger HCCs of > 5 mm (**P < 0.01). 
Figure 3: In vivo MRI and post-mortem verifications of a representative micro-HCC with nearly complete necrosis 
induced by CA4P. (A) In vivo MRI findings of microcancer Tumor 1 (arrows): on T2WI, hyperintense before treatment and increased 
hyperintensity at 12 h (a1-b1); on precontrast T1WI, there were no obvious changes with nearly isointensity (a2-b2); on ADC map, 
moderate hyperintense at baseline and increased signal at 12 h (a3-b3); and on CE-T1WI, minimal enhancement at baseline and delayed 
contrast enhancement at 12 h after CA4P treatment (a4-c4). (B) Corresponding microangiography (a) depicted scarce tumor vascularity. 
Macrophotograph (b) and histopathology (H&E staining; c1, × 25 original magnification, scale bar = 400 μm; c2, × 200 original 
magnification, scale bar = 50 μm. NT: necrotic tumor; VT: viable tumor; L: liver.) revealed nearly complete intratumoral necrosis. (C) 
Quantification of ADCs derived from DWI. ADCperf (a) indicated blood perfusion sharply decreased in cirrhotic liver after CA4P treatment 
(**P < 0.01) with a decline also in tumor. Compared with live perfusion, tumor perfusion was less both before and after treatment 
(*P < 0.05). ADCdiff (b) slightly increased at 12 h suggestive of CA4P-induced intratumoral necrosis, while liver ADCdiff did not show significant 
change. (D) Quantification of DCE-MRI biomarkers. Quantitative parameter, percentile value of volume transfer constant Ktrans (a, *P < 0.05) 
as well as semi-quantitative parameters including percentile values of area under curve AUC30 (b, ***P < 0.001) and maximal initial slope 
ISpeak (c) and time to peak TTP (d), consistently reflected a reduction of blood flow in necrotic microcancers at 12 h.
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suggested neovasculature in cirrhotic parenchyma could 
also be attacked by CA4P (Figure 4B). 
DISCUSSION
The development of HCCs in the cirrhotic liver is 
characterized by multistep remodeling of tumor blood 
supply [24]. HCCs are generally hypervascularized solid 
tumors [24] that are fed predominantly by hepatic arterial 
branches [25]. But, small HCCs in human patients (< 
2 cm) are frequently not hypervascular [26] and can be 
further divided into two types, namely vaguely nodular, 
well-differentiated tumor (“early” HCC), and distinctly 
nodular lesion with similar histological feature to “classic” 
large HCC (small HCC of distinctly nodular type) [27]. 
Likewise, in DENA-induced rat liver cancer, it has been 
shown that hepatic tumor nodules smaller than 5 mm 
are fundamentally supplied by the portal vein, which is 
Figure 4: Post-morterm verifications of CA4P-induced necrosis in micro-HCCs on liver cirrhosis. (A) Microangiography 
(a1-f1) suggested sparser vessel density appeared in Tumor 2–6 where tumoral necrosis occurred, and large vascular lakes existed in 
Tumor 7 where rare tumoral necrosis was induced. Photomacrographs (a2-f2) and microscopies (H&E staining; a3-f3, × 12.5 original 
magnification, scale bar = 800 μm; a4-f4, × 100 original magnification, scale bar = 100 μm.) verified nearly complete necrosis occurring in 
Tumor 2–5, partial necrosis induced in Tumor 6, and rare necrosis in Tumor 7 (NT: necrotic tumor; VT: viable tumor; L: liver; V: vascular 
lake.). Patchy necrosis (arrowheads) was also scattered in the sounding cirrhotic liver of Tumor 2, 3 and 7. CD34-PAS dual staining (a5-
f5, × 200 original magnification, scale bar = 50 μm) revealed rare CD34-positive vascular channels in the acute necrotic areas in Tumor 
2–5, abundant CD34-positive mature vessels in the viable area of Tumor 6 that survived CA4P treatment, and strong and diffuse CD34 
expression in tumor cells that lined up the enlarged vascular lakes in Tumor 7. (B) Histopathology (H&E staining; a1, b1, × 50 original 
magnification, scale bar = 200 μm; a2, b2, × 200 original magnification, scale bar = 50 μm.) demonstrated necrosis foci (arrowheads) 
existed in the cirrhotic liver psarenchyma (NL: necrotic liver; VL: viable liver.).
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distinguishing from the large rat HCCs [20]. Given the 
diverse HCC vascularity, it would be valuable to analyze 
the early HCCs as a subgroup of micro-HCCs.
In this preclinical study, we reported for the first 
time that nearly complete CA4P therapeutic responses was 
found in certain microcancers (<5mm) of DENA-induced 
primary HCCs in rats, along with treatment-induced 
necrotic foci scattered on the cirrhotic liver background. 
Perfusion and diffusion calculated from ADC, as well as 
quantitative and semi-quantitative parameters derived 
from DCE-MRI, helped to portray early tumoral vascular 
reaction and necrosis, secondary to the dramatic fall 
of entire liver blood supply. Two main factors may 
synergistically contribute to this superior efficacy of 
CA4P in microcancers, 1) avascular and/or hypovascular 
features in such “early HCCs”, “small HCCs” or micro-
HCCs [17, 18, 26]; and 2) neovascularization in cirrhotic 
liver parenchyma also vulnerable to CA4P mediated 
antitubulin effects. Consequently, vascular shutdown and 
ischemic necrosis in the host liver could render the micro-
HCCs deprived from vital nutrition, leading to the present 
paradoxical findings. 
Liver cirrhosis has been widely considered as 
a high-risk precancerous condition which could be 
due to chronic viral hepatitis, alcohol, aflatoxin, etc. 
[28, 29]. Application of carcinogen DENA in rodents could 
simulate this pathological progression and eventually 
induces primary liver cancers with underlying liver 
cirrhosis [30]. Development of liver fibrosis is associated 
with pathological angiogenesis that progressively forms 
the abnormal angioarchitecture distinctive of cirrhotic 
liver [31, 32]. Notably, CA4P-induced necrosis in 
cirrhotic liver as seen in our study seems to suggest that 
neo-angiogenesis in liver fibrogenic progress might share 
something in common with tumor angiogenesis that can 
be equally targeted by VDAs. However, the mechanisms 
remain to be explored.
We recognize the limitations of our study. Although 
DWI has been a renowned imaging marker to monitor 
early VDA-induced tumor vascular responses and further 
indicate tumoral necrosis [10, 23], the calculated ADC 
changes concerning tumor perfusion and diffusion in 
our study did not appear so significantly. The associated 
reasons might be the increased MRI artifact when tumor 
volume is too small, and the limited cases of recruited 
hepatic microcancers in this study. Secondly, considering 
the significant alterations of blood supply in the cirrhotic 
liver and the lack of reports regarding such side effect 
of VDA in liver cirrhosis in the clinical studies, it would 
be valuable to conduct parallel studies to compare VDA 
effects in normal and cirrhotic livers. In addition, the body 
size disparity between human and rodent may arouse 
suspicion about the relevance between these rat-specific 
findings and the similar effects in human patients, which 
calls for further validation in the human clinical trials.
MATERIALS AND METHODS
Animals and reagents
Male Sprague Dawley (SD) rats were purchased 
from Charles River Breeding Laboratories, Inc. (St. 
Aubain les Elbeuf, France). Diethylnitrosamine (DENA, 
N0258) was procured from Sigma-Aldrich (St. Louis, 
MO, USA). CA4P (C643025) was obtained from Toronto 
Research Chemical Inc. (Toronto, Canada). MRI contrast 
agent Dotarem (Gd-DOTA, Gadoterate meglumine; 
Dotarem®, Guerbet, France), barium sulfate suspension 
(Micropaque®, Guerbet, France) and gas anesthetic 
isoflurane (Forane®; Baxter Healthcare, Deerfield, IL, 
USA) were also commercially obtained. The rabbit 
monoclonal antibody against CD34 was purchased from 
Abcam (ab62738). 
In vivo MRI
Images were acquired on a clinical 3.0T MRI 
scanner (MAGNETOM Prisma; Siemens, Erlangen, 
Germany) and a human wrist coil (Hand/Wrist 16, A 3T 
Tim coil, Siemens). Twenty axial images were acquired, 
with a slice thickness of 2.0 mm and a gap of 0.4 mm. 
T2-weighted (repetition time, 4000 ms; echo time, 70 
ms; flip angle, 150°; field of view, 75 × 56 mm2; matrix, 
256 × 192) and T1-weighted (repetition time, 626 ms; 
echo time, 15 ms; flip angle, 160°; field of view, 75 × 56 
mm2; matrix, 256 × 192) turbo spin echo turbo spin echo 
(TSE) images (T2WI, T1WI) were performed weekly 
to monitor tumor growth, while T2WI, T1WI, DWI, 
DCE and consecutive contrast-enhanced (CE)-T1WIs 
were acquired to evaluate CA4P treatment. For DWI, a 
2-dimensional SE echo-planar imaging (EPI) sequence 
(repetition time, 3500 ms; echo time, 62 ms; flip angle, 
90°; field of view, 136 × 74 mm2; matrix, 96 × 52) with 8 
b values (0, 50, 100, 150, 400, 600, 800 and 1000 seconds/
mm2) was acquired. For DCE, a T1-weighted gradient 
echo (GE) sequence (repetition time, 7 ms; echo time, 2.45 
ms; flip angle, 15°; field of view, 61 × 89 mm2; matrix, 
132 × 192) was acquired. After a precontrast baseline of 
30 measurements, a bolus injection of 0.02 mmol/kg Gd-
DOTA was conducted. The entire acquisition lasted for 
100th measurement. Immediately after DCE, a bolus of 
0.2 mmol/kg Gd-DOTA was injected before a series of 
CE-T1WIs were acquired.
Experimental design
This animal experiment was carried out in compliance 
with European and national regulations after approval from 
KU Leuven university ethics committee for animal care and 
use. All in vivo procedures including gavage feeding, tumor 
implantation, drug injection and imaging were performed 
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under gas-anesthesia with 2% isoflurane in the mixture 
of 20% oxygen and 80% room air using a gas anesthesia 
system (Harvard Apparatus, Holliston, MA, USA).
As illustrated in Figure 1, multifocal primary liver 
cancers were established in 19 male Sprague Dawley 
(SD) rats weighting 300–350 g by 8-week daily gavage 
feeding of DENA at 10 mg/kg/day. Tumor growth was 
monitored weekly by MRI from the 9th week after DENA 
administration until the largest tumor lesion attained 
more than 1 cm in diameter. All recruited tumor-carrying 
rats received single intravenous injection of CA4P at 
10 mg/kg. T2WI, T1WI, DWI, DCE and CE-T1WI were 
performed 4 h before and 12 h after CA4P therapy. Rats 
were euthanized after the last time point of MRI for 
postmortem microangiography and histopathology.
MR image analyses
Image analysis was conducted using the built-in 
software on the Siemens workstation (version Numaris/4 
Syngo MR A30), MeVisLab (version 2.6.2, MeVis 
Medical Solutions AG, Bremen, Germany) and MatLab 
(version R2015b, The MathWorks, Natick, MA, USA). All 
the following measurements were acquired by 3 authors 
with consensus.
Measurement of tumor diameter
On T2WI, tumor diameter was manually measured 
from the tumor-containing image with the largest tumor 
cross section at 4 h before treatment.
Separate calculation of tumor ADCs
On DWI, tumor area was manually contoured with 
an operator-defined region of interest (ROI) on all tumor-
containing images. ADC map was derived from DWI 
according to the following mono-exponential formula: 
Si = S0 × exp (-bi × ADC), in which Si is the signal 
intensity (SI) measured on the ith b value image, bi is the 
corresponding b value, and S0 is a variable estimating the 
intrinsic SI (for b = 0 seconds/mm2). 
For the calculation of different ADC values, 
microcancers were freehand delineated only on the 
central slices with the largest cross-sectional areas on the 
original DWIs at the b value of 1000 s/mm2, in order to 
avoid partial volume effects. The delineations of each 
microcancer lesion and liver were copied to all images 
with different b values automatically. The average SI per 
tumor and per b value was then determined. The difference 
between ADClow (b = 0, 50 and 100 s/mm
2) and ADChigh 
(b = 400, 600 and 1000 s/mm2) was defined as ADCperf to 
reflect the tissue micro-vessel or capillary perfusion, while 
ADChigh was defined as ADCdiff  [33].
Quantitative and semi-quantitative analyses of T1-
weighted DCE
For the calculation of multiple DCE parameters, 
ROI of tumor was freehand delineated on the central 
slices with the largest cross-sectional areas; ROI of 
abdominal aorta was manually delineated from 4 
consecutive slices for defining arterial input function; 
ROI of cirrhotic liver was manually delineated on 4 
representative slices each from median, left, right and 
caudate lobes. All ROIs were copied to all measurements 
automatically. Since a low gadolinium dose was used, a 
linear relation between the amount of contrast agent in 
the tissue and the resultant difference in relaxation time 
could been assumed [34]. Quantitative parameter Ktrans, 
the volume transfer constant between blood plasma and 
EES, was generated by fitting Tofts and Kermode model 
[35, 36]. Semi-quantitative parameters, such as area under 
the time-signal intensity curve (AUC30), maximal initial 
slope (ISpeak) and time to peak (TTP) were derived from 
the enhancement curve [37]. 
Digital microangiography  
After the last MRI scanning, rats were anesthetized 
by an intraperitoneal injection of pentobarbital at 50 
mg/kg. Then laparotomy was performed with blood 
collected via postcava and abdominal aorta cannulated, 
through which barium suspension was injected before 
the entire tumor-bearing liver was excised. With a 
digital mammography unit (Em-brace; Agfa-Gevaert, 
Mortsel, Belgium), postmortem hepatic arteriography 
was made at 26 kV, 32 mAs to document changes in 
tumor vascularity. The livers were then fixed and sliced 
into 3-mm sections in the axial plane corresponding to 
the MR images, and these sections were radiographed at 
26 kV, 18 mAs.
Histopathological analyses
After microangiography, the tumor sections were 
paraffin imbedded, sliced into 5 µm thickness and stained 
with hematoxylin and eosin (H&E) for microscopic 
analysis using an Axiovert 200 M microscope equipped 
with an AxioCam MR monochrome digital camera (Carl 
Zeiss Inc, Gottingen, Germany) and by AxioVision 4.8 
software.
Diagnosis of HCCs 
Due to the high analogy to the histopathological 
progression observed in human liver cancer, rat primary 
HCCs were diagnosed according to the classical 
histomorphologic features: malignant hepatocytic tumors, 
often well vascularized, with wide trabeculae (>3 cell 
layers), noticeable acinar pattern, small cell changes, 
cytologic atypia, prominent nucleoli, mitotic activity, 
vascular invasion, absence of Kupffer cells, missing 
portal triads, and the loss of the reticulin network [29]. 
The differentiation of rat HCCs was further classified 
into Grade I-IV using a modified 4-scale Edmondson 
and Steiner system [29]. Tumor vascularity was semi-
quantificationally scored from + to ++++ (Table 1).
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Calculation of CA4P-induced intratumoral necrosis
Digital images of tumor slices at a magnification 
of 12.5 were used to estimate the percentage of tumor 
necrosis by ImageJ software [38]. Briefly, regions of 
interest were delineated around the entire tumor and 
the necrotic tumor, respectively, to get ‘necrotic ratio 
on each section’. For each tumor section, the axial slide 
representing this tumor block was selected as ‘section 
area’. Tumor necrosis on each H&E stained slice was 
estimated independently by 2 pathologists, and calculated 
with the equation: Intratumoral necrosis ratio (%) = ∑ 
[Necrotic ratio on each section (%) × section area (mm2)] 
× section thickness (mm) / [4/3π r3] (mm3). 
CD34 and periodic acid-Schiff (PAS) dual 
staining
To identify matrix-associated vascular channels of 
HCCs, CD34 immunohistochemical staining was first 
performed. Paraffin-embedded slices in 5 µm thickness were 
deparaffinized, rinsed and exposed to 3% H2O2 for 10 min 
at 37°C to block the activity of endogenous peroxidase. The 
slices were then blocked with 10% goat serum for 30 min at 
room temperature, before incubation with a CD34 antibody 
at a dilution of 1:150 overnight at 4°C. The reactions were 
visualized with the Histostain-SP-Broad-Spectrum kit 
(Invitrogen, Grand Island, NY, USA). Following CD34 
immunostaining, slices were rinsed and treated with 
0.5% PAS (American MasterTech, CA, USA) for 15 min, 
counterstained with hematoxylin and cover-slipped.
Statistical analysis
Statistical analyses were carried out by GraphPad 
Prism (version 7.02, GraphPad Software Inc, La Jolla, 
CA, USA). The Pearson’s correlation coefficient was 
calculated between percentile tumoral necrosis calculated 
by histopathology and tumor diameter measured from 
T2WI. Numerical data were presented as mean ± standard 
errors of the mean (SEM) or standard deviation (SD). 
Comparison of percentile tumoral necrosis and DCE 
parameters were performed by unpaired two-way t-test; 
results of ADCs between tumor and liver background were 
compared by two-way ANOVA. A significant difference 
was concluded for P < 0.05. 
CONCLUSIONS
On balance, the present findings may shed some 
light on the preventative effect of CA4P on recurrent 
hepatoma foci as well as intrahepatic micrometastases 
in cirrhotic background. But on the other hand, such a 
phenomenon also raise the awareness to protect liver 
function during future CA4P therapy principally in 
patients with underlying chronic hepatic diseases being 
developed into cirrhosis, for potential formation of 
CA4P-induced necrosis in cirrhotic liver and consequent 
liver failure. These may be of potential value for planning 
further clinical applications of CA4P in human subjects 
with HCCs and liver cirrhosis.
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